Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HCW Biologics (HCWB) Shares Outstanding (Weighted Average) (2020 - 2025)

HCW Biologics (HCWB) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 139.01% year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Sep 2025, up 139.01%, and an annual FY2024 reading of $38.8 million, up 7.97% over the prior year.
  • Shares Outstanding (Weighted Average) was $2.3 million for Q3 2025 at HCW Biologics, up from $1.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $44.7 million in Q1 2025 and bottomed at $938087.0 in Q2 2024.
  • Average Shares Outstanding (Weighted Average) over 5 years is $23.9 million, with a median of $35.8 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) soared 639.24% in 2022, then plummeted 97.39% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $18.8 million in 2021, then surged by 90.84% to $35.8 million in 2022, then increased by 0.3% to $35.9 million in 2023, then grew by 7.97% to $38.8 million in 2024, then plummeted by 94.17% to $2.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for HCWB at $2.3 million in Q3 2025, $1.8 million in Q2 2025, and $44.7 million in Q1 2025.